β-catenineremmende peptoïde

β-catenin inhibitory peptoid (compound 13) inhibits the β-catenin:TCF interaction with an IC50 of 5.44 µM. β-catenin inhibitory peptoid inhibits both Wnt (IC50 of 0.105 µM) and androgen receptor (AR) -signaling (IC50 of 1.02 µM) in prostate cancer cell lines. β-catenin inhibitory peptoid markedly diminishes cell proliferation of prostate cancer cell lines[1].

2579070-02-1

12352209

Androgen Receptor; Wnt; β-catenin

Stem Cell/Wnt; Vitamin D Related/Nuclear Receptor

Cancer

O=C1N(C2=CC(OC)=CC(OC)=C2)CC(N(CC(N(CC(N(CC(N[C@@H](C(N(C1)CCC3=C(C=CC=C3)OC4=CC=CC=C4)=O)C)=O)[C@H](C5=CC=C(C=C5)OC)C)=O)[C@H](C6=CC=C(C=C6)OC)C)=O)CCCOC(C)C)=O

C59H72N6O12

1057.24

[1]Jeffrey A Schneider, et al. Design of Peptoid-peptide Macrocycles to Inhibit the β-catenin TCF Interaction in Prostate Cancer. Nat Commun. 2018 Oct 23;9 (1) :4396.

Room temperature

http://file.medchemexpress.com/batch_PDF/HY-P11007/

Peptides

No Development Reported